Document is current
Any future updates will be listed below
-
Authors
Nettis, Eustachio
Brussino, Luisa
Patella, Vincenzo
Bonzano, Laura http://orcid.org/0000-0002-8933-4626
Detoraki, Aikaterini
Di Leo, Elisabetta
Sirufo, Maria Maddalena
Caruso, Cristiano
Lodi Rizzini, Fabio
Conte, Mariaelisabetta
Yacoub, Mona-Rita
Triggiani, Massimo
Ridolo, Erminia
Macchia, Luigi
Rolla, Giovanni
Brancaccio, Raffaele
De Paulis, Amato
Spadaro, Giuseppe
Di Bona, Danilo
D’Uggento, Angela Maria
Ginaldi, Lia
Gaeta, Francesco
Nucera, Eleonora
Jaubashi, Kliljeda
Villalta, Danilo
Dagna, Lorenzo
Ciotta, Domenico
Pucciarini, Francesco
Bagnasco, Diego
Celi, Giorgio
Chieco Bianchi, Fulvia
Cosmi, Lorenzo
Costantino, Maria Teresa
Crivellaro, Maria Angiola
D’Alò, Simona
del Biondo, Pietro
Del Giacco, Stefano
Di Gioacchino, Mario
Di Pietro, Linda
Favero, Elisabetta
Gangemi, Sebastiano
Guarnieri, Gabriella
Heffler, Enrico
Leto Barone, Maria Stefania
Lombardo, Carla
Losa, Francesca
Matucci, Andrea
Minciullo, Paola Lucia
Parronchi, Paola
Passalacqua, Giovanni
Pucci, Stefano
Rossi, Oliviero
Salvati, Lorenzo
Schiappoli, Michele
Senna, Gianenrico
Vianello, Andrea
Vultaggio, Alessandra
Baoran, Yang
Incorvaia, Cristoforo
Canonica, Giorgio Walter
- License Information
-
More Information
Article History
Received: 24 February 2022
Accepted: 13 April 2022
First Online: 19 May 2022
Declarations
:
: The study protocol (#75/21) was approved by the ethical committee of Naples University Hospital, Italy. Informed consent was obtained from all patients who agreed to participate to this study.
: Not applicable.
: PP: GSK, Novartis (fees for lectures), LeoPharma (expert board); DB: GSK, Novartis, Astra, Sanofi (speaker); MC: GSK, Sanofi (speaker); EH: Sanofi, Regeneron, Novqrtis, GSK, Astrazeneca, Circassia, Stallergenes-Greer, Nestlè Purina (speaker and advisory board), AD: Sanofi, Glaxo-Smith Kline (advisory board), SDG: AstraZeneca, GSK, Novartis, Sanofi (advisory board and speaker). EN, LB, VP, LB, EDL, MMS, MT, ER, LM, GR, RB, GS, DDB, ADP, FCB, AMD, CC, CL, LG, MDG, KJ, EN, LD, DC, GG, FG, GS, DV, FLR, GP, FP, GC, LC, MTC, MAC, SD, PDB, LDP, EF, SG, MSLB, FL, AM, MRY, PLM, SP, OR, LS, MS, AV, AV, YB, CI, GWC have no competing interests.
